A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II
Authors:
- CLAIM Study investigatorsCICLAIM Study investigators
- 1 July 2001
- journal article
- clinical trial
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 15 (7) , 475-480
Abstract
An 8-week, multicentre (72 sites in the US), double-blind, randomised, parallel group, forced titration study compared the antihypertensive efficacy of candesartan cilexetil and losartan. A total of 611 patients with essential hypertension (diastolic blood pressure 95 to 114 mm Hg) were randomised initially to candesartan cilexetil 16 mg once daily or losartan 50 mg once daily. After 2 weeks of randomised treatment, the doses of candesartan cilexetil and losartan were doubled to 32 mg and 100 mg once daily and continued respectively for 6 weeks. At week 8, candesartan cilexetil lowered the blood pressure (BP) at 24 h (trough), 6 h (peak) and 48 h post dose to a significantly greater extent (P < 0.05) than losartan: candesartan cilexetil lowered trough BP by 13.4/10.5 mm Hg, peak BP by 15.5/12.9 mm Hg and 48-h BP by 10.5/9.9 mm Hg compared to a reduction of trough BP by 10.1/9.1 mm Hg, peak BP by 12.0/9.5 mm Hg, and 48-h BP by 5.9/7.0 mm Hg by losartan. The responder and control rates were numerically higher in the candesartan cilexetil group, but the differences did not reach statistical significance; the responder rates were 58.8% for the candesartan cilexetil group and 52.1% for the losartan group and control rates were 49.0% for the candesartan cilexetil group and 44.6% for the losartan group. Overall, both treatment regimens were well tolerated. A total of 15 of the 611 (2.5%) patients withdrew from the study due to an adverse event, including nine (2.9%) in the candesartan cilexetil group and six (2.0%) in the losartan group. In conclusion, this forced titration study confirms that candesartan cilexetil is more effective in lowering BP than losartan when compared at once daily maximum doses.Keywords
This publication has 10 references indexed in Scilit:
- Antihypertensive Efficacy of Candesartan in Comparison to Losartan: The CLAIM StudyThe Journal of Clinical Hypertension, 2001
- Angiotensin II antagonists for hypertension: are there differences in efficacy?American Journal of Hypertension, 2000
- Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptorsBiochemical Pharmacology, 2000
- Angiotensin II receptor antagonistsThe Lancet, 2000
- A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients A placebo-controlled, forced titration studyAmerican Journal of Hypertension, 1999
- Mechanistic Differences of Various AT1-Receptor Blockers in Isolated Vessels of Different OriginHypertension, 1999
- Carvedilol and the Food and Drug Administration Approval ProcessControlled Clinical Trials, 1999
- The Antihypertensive Effect and Tolerability of Candesartan Cilexetil, a New Generation Angiotensin II Antagonist, in Comparison with LosartanBlood Pressure, 1998
- Characterization of the Angiotensin II Receptor Antagonist TCV-116 in Healthy VolunteersHypertension, 1995
- Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonistClinical Pharmacology & Therapeutics, 1992